Squamoproliferative lesions arising in the setting of BRAF inhibition.

  title={Squamoproliferative lesions arising in the setting of BRAF inhibition.},
  author={Nathan Tobias Harvey and Michael Millward and Benjamin Andrew Wood},
  journal={The American Journal of dermatopathology},
  volume={34 8},
In recent years, there has been increasing use of several novel agents that specifically target the V600E BRAF mutation in melanoma and other malignancies. One significant side effect of these drugs is the development of cutaneous squamoproliferative lesions, variously described as keratoacanthomas (KAs) and well-differentiated squamous cell carcinomas. We undertook a histopathological review of lesions excised from patients on BRAF inhibitor therapy, and found that 73% of lesions were… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…